D&D Pharmatech Inc. (KOSDAQ:347850)

D&D Pharmatech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	12,258	32,884	30,014	15,642	25,504	75,958
Short-Term Investments	140,000	0	-	-	-	-
Cash & Short-Term Investments	152,258	32,884	30,014	15,642	25,504	75,958
Cash Growth	280.68%	9.56%	91.88%	-38.67%	-66.42%	25.32%
Accounts Receivable	168.16	201.92	3,141	263.95	41.84	12.46
Other Receivables	6,836	1,773	2,383	1,165	286.31	94.12
Receivables	7,004	1,975	5,524	1,429	328.15	106.58
Prepaid Expenses	1,300	996.48	4,047	2,356	7,330	5,507
Other Current Assets	24,599	15,132	209.3	138.64	193.46	121.45
Total Current Assets	185,161	50,988	39,794	19,565	33,355	81,692
Property, Plant & Equipment	4,906	5,636	7,729	6,422	3,024	10,966
Long-Term Investments	97,684	9,248	14,242	10,776	12,326	-
Goodwill	2,195	2,043	2,093	9,905	9,735	34,754
Other Intangible Assets	28,594	28,308	32,476	31,615	34,246	122,689
Long-Term Accounts Receivable	0.43	1.56	3.84	179.43	6.72	7.68
Other Long-Term Assets	1,390	1,315	1,162	740.73	948.44	1,000
Total Assets	319,930	97,539	97,500	79,204	93,642	251,109

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	1,455	940.93	4,468	2,080	6,803	7,647
Short-Term Debt	-	-	1,830	1,521	19,225	34,836
Current Portion of Leases	2,093	1,978	1,772	1,493	1,583	1,276
Other Current Liabilities	3,257	2,500	3,044	2,393	27,312	23,100
Total Current Liabilities	6,806	5,419	11,115	7,487	54,923	66,859
Long-Term Debt	109,558	-	-	-	-	-
Long-Term Leases	3,443	4,267	6,180	5,121	6,425	7,463
Pension & Post-Retirement Benefits	-	-	-	13	-	49.7
Long-Term Deferred Tax Liabilities	7,742	7,671	8,811	8,564	9,239	33,367
Other Long-Term Liabilities	58,289	1,204	1,825	2,801	4,536	5,042
Total Liabilities	185,837	18,560	27,931	23,986	75,123	112,781

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	22,919	21,768	5,284	4,649	4,034	4,028
Additional Paid-In Capital	447,584	333,829	337,015	297,522	268,925	268,673
Retained Earnings	-350,771	-332,916	-309,361	-289,676	-293,610	-157,543
Comprehensive Income & Other	14,997	56,813	37,174	34,154	30,091	16,951
Total Common Equity	134,729	79,494	70,112	46,650	9,440	132,109
Minority Interest	-635	-514.69	-542.93	8,568	9,079	6,219
Shareholders' Equity	134,094	78,979	69,569	55,218	18,519	138,328
Total Liabilities & Equity	319,930	97,539	97,500	79,204	93,642	251,109

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	115,094	6,245	9,782	8,134	27,233	43,575
Net Cash (Debt)	37,164	26,639	20,231	7,508	-1,729	32,383
Net Cash Growth	12.29%	31.67%	169.47%	-	-	-40.99%
Net Cash Per Share	851.29	606.37	498.86	200.09	-53.64	983.80
Filing Date Shares Outstanding	45.84	43.54	42.27	37.2	32.27	32.23
Total Common Shares Outstanding	45.84	43.54	42.27	37.2	32.27	32.23
Working Capital	178,356	45,569	28,680	12,078	-21,568	14,834
Book Value Per Share	2939.26	1825.96	1658.58	1254.17	292.55	4099.37
Tangible Book Value	103,940	49,143	35,544	5,129	-34,541	-25,333
Tangible Book Value Per Share	2267.56	1128.81	840.82	137.90	-1070.43	-786.09
Machinery	3,257	3,148	3,198	3,250	3,441	3,454
Construction In Progress	-	-	-	1.7	-	4.78

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 22, 2026

Data Sources Report a data error